Biologics for chronic rhinosinusitis with nasal polyps (CRSwNP)

J Allergy Clin Immunol. 2022 Mar;149(3):895-897. doi: 10.1016/j.jaci.2021.10.029. Epub 2021 Nov 6.

Authors

Glenis K Scadding¹, Guy W Scadding²

Affiliations

¹ Royal National ENT Hospital, University College Hospitals London, Division of Infection and Immunity, University College London, London, United Kingdom. Electronic address: g.scadding@ucl.ac.uk.
² Allergy and Clinical Immunology, Imperial College, London, United Kingdom.

PMID: 34752829
DOI: 10.1016/j.jaci.2021.10.029

No abstract available

Keywords: CRSwNP; Chronic rhinosinusitis with nasal polyps; JAK-selective inhibitors; SNOT-22; biologics; omalizumab.

Publication types

Editorial
Comment

MeSH terms

Biological Products* / therapeutic use
Chronic Disease
Humans
Nasal Polyps* / drug therapy
Rhinitis* / drug therapy
Sinusitis* / drug therapy

Substances

Biological Products